Novartis Galvus India Case: Wockhardt Pulls Back?

Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.

The Delhi High Court has disposed of a case pertaining to Novartis AG's DPP-4 inhibitor for diabetes, vildagliptin, after challenger Wockhardt Ltd. indicated that it would "take steps" to withdraw the application for revocation of the patent concerning the product pending before India's Intellectual Property Appellate Board (IPAB).

Wockhardt's counsel assured the court of the firm's intent to pull back the application and also abide by certain undertakings...